Aurinia Pharmaceuticals Inc (AUPH)
$7.12 $0.06 (0.93%) 4:37 PM 10/05/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$1.04B -
Day's Range
$6.99 - $7.16 -
Volume
1,115,731 -
52 Week Low / High
$4.71 - $10.05 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 3
- Strong Buy
- 3
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $14.00
- Target Price
Company News
-
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis — Sep 24th, 2024
ROCKVILLE, Md. & EDMONTON, Alberta, September 24, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in co...
-
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability — Sep 27th, 2024
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to t...
Portfolio
Comprised of 1 portfolios